BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 15459432)

  • 1. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier.
    Deane R; Wu Z; Zlokovic BV
    Stroke; 2004 Nov; 35(11 Suppl 1):2628-31. PubMed ID: 15459432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.
    Deane R; Zlokovic BV
    Curr Alzheimer Res; 2007 Apr; 4(2):191-7. PubMed ID: 17430246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease.
    Jaya Prasanthi RP; Schommer E; Thomasson S; Thompson A; Feist G; Ghribi O
    Mech Ageing Dev; 2008 Nov; 129(11):649-55. PubMed ID: 18845178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two β-strands of RAGE participate in the recognition and transport of amyloid-β peptide across the blood brain barrier.
    Kim SJ; Ahn JW; Kim H; Ha HJ; Lee SW; Kim HK; Lee S; Hong HS; Kim YH; Choi CY
    Biochem Biophys Res Commun; 2013 Sep; 439(2):252-7. PubMed ID: 23973487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic targets in the neurovascular pathway in Alzheimer's disease.
    Zlokovic BV
    Neurotherapeutics; 2008 Jul; 5(3):409-14. PubMed ID: 18625452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.
    Sagare AP; Bell RD; Zlokovic BV
    Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
    Deane R; Bell RD; Sagare A; Zlokovic BV
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.
    Bell RD; Zlokovic BV
    Acta Neuropathol; 2009 Jul; 118(1):103-13. PubMed ID: 19319544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.
    Yamazaki Y; Kanekiyo T
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of High Cholesterol Regulation of LRP1 and RAGE on Aβ Transport Across the Blood-Brain Barrier in Alzheimer's Disease.
    Zhou R; Chen LL; Yang H; Li L; Liu J; Chen L; Hong WJ; Wang CG; Ma JJ; Huang J; Zhou XF; Liu D; Zhou HD
    Curr Alzheimer Res; 2021; 18(5):428-442. PubMed ID: 34488598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunodistribution of amyloid beta protein (Aβ) and advanced glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients.
    Maślińska D; Laure-Kamionowska M; Taraszewska A; Deręgowski K; Maśliński S
    Folia Neuropathol; 2011; 49(4):295-300. PubMed ID: 22212919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells.
    Wilhelmus MM; Otte-Höller I; van Triel JJ; Veerhuis R; Maat-Schieman ML; Bu G; de Waal RM; Verbeek MM
    Am J Pathol; 2007 Dec; 171(6):1989-99. PubMed ID: 18055545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier.
    Osgood D; Miller MC; Messier AA; Gonzalez L; Silverberg GD
    Neurobiol Aging; 2017 Sep; 57():178-185. PubMed ID: 28654861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral uptake transport.
    Guo YX; He LY; Zhang M; Wang F; Liu F; Peng WX
    Neuroscience; 2016 May; 322():28-38. PubMed ID: 26820600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature.
    Carnevale D; Mascio G; D'Andrea I; Fardella V; Bell RD; Branchi I; Pallante F; Zlokovic B; Yan SS; Lembo G
    Hypertension; 2012 Jul; 60(1):188-97. PubMed ID: 22615109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.
    Leclerc E; Sturchler E; Vetter SW; Heizmann CW
    Rev Neurosci; 2009; 20(2):95-110. PubMed ID: 19774788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain.
    Zlokovic BV; Deane R; Sagare AP; Bell RD; Winkler EA
    J Neurochem; 2010 Dec; 115(5):1077-89. PubMed ID: 20854368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice.
    Chen F; Dong RR; Zhong KL; Ghosh A; Tang SS; Long Y; Hu M; Miao MX; Liao JM; Sun HB; Kong LY; Hong H
    Neuropharmacology; 2016 Feb; 101():123-36. PubMed ID: 26211973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
    Deane R; Sagare A; Zlokovic BV
    Curr Pharm Des; 2008; 14(16):1601-5. PubMed ID: 18673201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.